: Targets tumor necrosis factor (TNF), a central inflammatory pathway addressed by biologics such as Humira and Enbrel Focuses on oral small molecules designed to deliver biologic-like efficacy Uses a proprietary AI-driven platform that models protein motion to identify new binding approaches Series A co-led by Lightstone Ventures and Samsara BioCapital, with participation from Roivant Sciences, YK Bioventures, and Eurofarma Ventures The company was founded by Woody Sherman, PsiTheras founder and chief innovation officer, and is led by Eric Shaff, CEO
The medication slows gastric emptying, reduces appetite, and enhances glucose-dependent insulin secretion without restricting specific foods
These AEs typically manifested earlier in the study during the dose initiation and escalation phases
EPO / Connect Plan: In-network-only access without a referral requirement
Hello Lemongals
Vilsboll T, Christensen M, Junker A, et al